A vs. RVMD: Agilent vs. Revolution Medicines Stock Comparison

Company Profile

Agilent (A) and Revolution Medicines (RVMD) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but A is classified in Life Sciences Tools & Services while RVMD is classified in Biotechnology.

Agilent (A) has more than two decades of public-market history since November 18, 1999, whereas Revolution Medicines (RVMD) listed on February 13, 2020 and has a much shorter record to draw on.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Revolution Medicines (RVMD) reports a negative ROE of -93.56%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Agilent (A) reports 20.97%, ranking against industry peers normally.

Agilent (A) at 19.53% converts revenue to bottom-line profit above its industry’s benchmark range, while Revolution Medicines (RVMD) at 0.00% keeps roughly the typical share for its industry.

Revolution Medicines (RVMD) reports a negative operating margin of -188.88%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Agilent (A) reports 25.56%, ranking against industry peers normally.

Profitability Metrics

Growth

Only one side can be read here: Agilent (A) reports revenue growth of 6.73%, ranked against its industry; Revolution Medicines (RVMD) has no revenue growth figure this period.

Only one side can be read here: Agilent (A) reports EPS growth of 3.16%, ranked against its industry; Revolution Medicines (RVMD) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Revolution Medicines (RVMD) at 8.36 keeps current ratio within its industry’s typical mid-range, while Agilent (A) at 2.05 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for A.

Both Agilent (A) at 0.56 and Revolution Medicines (RVMD) at 0.50 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

Revolution Medicines (RVMD) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Agilent (A) reports a yield of 0.59%, ranking against industry peers normally.

Revolution Medicines (RVMD) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Agilent (A) reports a payout of 19.98%, ranking against industry peers normally.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Agilent (A) trades at 34.47 times trailing earnings, ranked against its peers, while Revolution Medicines (RVMD) has no P/E ratio this period.

Agilent (A) at 6.68 prices around its industry’s typical P/S ratio, while Revolution Medicines (RVMD) at 210.51 clears its benchmark range — RVMD looks notably rich on sales.

Both look rich against book: Agilent (A) at 6.69 sits in the upper P/B ratio quartile, and Revolution Medicines (RVMD) at 17.31 prices even higher, above its industry range.

Valuation Metrics